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INTRODUCTION 
Muta%ons	in	the	isocitrate	dehydrogenase	(IDH)	1	or	2	gene	are	found	in	
approximately	23%	of	acute	myeloid	leukemia	(AML)	pa%ents.	IDH	
muta%ons	have	a	neomorphic	func%on	and	gain	the	ability	to	produce	the	
novel	molecule,	D-2-hydroxyglutarate	(D2HG).	
	
	
	
D2HG	produc%on	has	been	shown	to	cause	DNA	and	histone	
hypermethyla%on,	which	also	occurs	in	leukemia,	although	the	exact	
mechanism	by	which	it	does	so	is	unknown.	D2HG’s	ability	to	alter	the	
epigene%c	profile	of	DNA	also	affects	the	transcrip%onal	profile.	Histone	
methyla%on,	for	example,	allows	for	%ghter	packaging	of	gene%c	material	
which	prevents	access	by	the	transcriptome	and	thus	prevents	expression.	
Our	lab	seeks	to	explain	the	link	between	D2HG,	hypermethyla%on,	and	the	
phenotype	of	leukemia	because	we	hypothesize	that	AML	is	caused	in	part	
as	a	result	of	altering	the	epigenome	in	a	par%cular	way.	To	explore	this,	
our	lab	has	developed	a	H9	stem	cell	line	which	has	stably	incorporated	the	
specific	IDH2	R140Q	muta%on	behind	a	promoter	that	allows	transcrip%on	
in	the	presence	of	doxycycline	(DOX)	and	before	a	green	fluorescent	
protein	(GFP)	gene.		
Our	aim	is	to	use	this	cell	line	to	understand	what	D2HG	specifically	
contributes	that	can	lead	to	development	of	leukemia.	General	features	of	
leukemia	include	increased	cell	prolifera%on	and		a	block	to	differen%a%on.		
Therefore	our	lab	uses	these	phenotypes	as	parameters	to	study	the	onset	
of	cancer	in	the	stem	cells.	
The	purpose	of	this	experiment	was	to	characterize	the	paZern	of	growth		
in	cells	treated	with	DOX	and	to	confirm	that	this	was	correlated	with	the	
produc%on	of	the	mutant	enzyme.	Our	hypothesis	was	that	GFP,	as	an	
indicator	of	IDH2	R140Q,	would	increase	over	%me	of	treatment	and	that	
the	number	of	cells	would	also	increase,	as	is	seen	in	leukemia	cells.	
METHODS 
RESULTS 
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CONCLUSION 
•  DOX	treatment	of	the	H9	IDH2	R140Q	cells	causes	the	transcrip%on	
and	transla%on	of	GFP,	which	serves	as	a	marker	for	the	produc%on	
of	the	mutant	IDH	enzyme.	
•  GFP	posi%vity,	and	mutant	IDH	expression,	increase	over	the	course	
of	treatment	with	DOX,	which	allows	for	more	conclusive	research	
over	%me.		
•  DOX	treatment	over	%me	results	in	a	decreased	prolifera%on	from	
the	control	condi%on	in	H9	cells	that	is	the	opposite	of	what	is	
expected	in	a	cancer	phenotype.	
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Figure	1	
Figure	4:	Cells	were	treated	daily	with	a	1:1000	dilu%on	of	DOX	
from	a	1mg/mL	stock	solu%on.	At	each	%mepoint,	cells	were	
counted	by	hematocrit.	At	the	Day	6	%mepoint	for		-DOX	cells,		
cells	were	so	confluent	that	they	began	to	die	and	slough	off.	
Therefore	cells	were	split	instead	of	being	counted.	
FUTURE DIRECTIONS 
Figure	3:	GFP	posi%vity	was	determined	by	sejng	a	boundary,	as	
displayed	in	Figure	2,	for	–DOX	cells	which	would	be	GFP	nega%ve	
and	applying	that	boundary	to	the	+DOX	cells.	The	resul%ng	frac%on	
of	cells	that	fell	beyond	that	boundary	were	classified	as	GFP	
posi%ve.		
Figure	2:	Cells	
were	harvested	at	
each	%mepoint	
and	suspended	in	
1mL	of	PBS.	The	
cells	were	spun	
down	and	washed	
in	FACS	buffer	
over	three	rounds	
and	then	filtered	
to	obtain	a	single	
cell	suspension.	
Flow	cytometers	
were	used	to	
analyze	the	GFP	
posi%vity	in	the	
BLUFL1	range.	
Cells	displayed	
were	gated	using	
SSC	and	FSC	to	
determine	live	
cells.	
•  Cell	growth	is	largely	dependent	upon	type	of	%ssue.	Therefore	it	is	
likely	that	the	decreased	prolifera%on	is	a	stem	cell	specific	response	
to	D2HG.	Our	focus	in	the	future	and	currently	is	upon	iden%fying	
which	genes	are	differen%ally	regulated	between	stem	cells	and	
leukemia	samples	so	that	we	can	modify	the	stem	cells	to	become	a	
model	that	more	accurately	represents	progenitors	to	leukemia.		
•  Cancer	phenotype	is	iden%fied	by	increased	prolifera%on	and	
inhibited	differen%a%on.	In	this	experiment,	we	were	able	to	
understand	the	effects	of	D2HG	on	stem	cell	prolifera%on;	however,	
future	studies	will	follow	up	on	the	differen%a%on	ability	in	the	same	
cell	line.		
•  In	order	to	best	mimic	the	environment	that	leukemia	cells	exist	in,	
we	need	to	perform	future	experiments	to	quan%fy	the	amount	of	
D2HG	that	is	produced	by	DOX	treated	cells.	Then	we	can	alter	the	
concentra%on	of	DOX	so	that	cells	can	produce	a	concentra%on	of	
D2HG	that	is	similar	to	that	in		leukemia	samples.	
•  General	future	direc%on	once	this	model	has	been	adjusted		includes	
determining	the	histone	and	DNA	methyla%on	sequence	so	that	key	
methyla%on	sites	can	be	mapped	to	certain	phenotypes.	
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